Introduction:

Immunoglobulin therapy, also known as normal human immunoglobulin (NHIG), is the use of a mixture of antibodies (immunoglobulins) to treat a number of health conditions. These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barré syndrome, and certain other infections when a more specific immunoglobulin is not available. Based on formulation, it can be administered intravenously of subcutaneously.

The global Intravenous Immunoglobulin (IVIg) market size was estimated to be at USD XXX million in 2019, and is expected to grow at a CAGR of XX% during forecast period to reach USD XXX million in 2027.

Market Dynamics:

There is an increasing demand for the intravenous immunoglobulin which can be attributed to the increasing awareness of the patient regarding the various forms of immunodeficiencies. Intravenous immunoglobulins are increasingly and widely recognized as the treatment for a number of medical conditions primarily. The ability of intravenous immunoglobulin in efficient treatment of patients with immunodeficiencies, combined with advent of new diagnostic procedures for the determination of the form of immunodeficiency is further expected to boost the market growth. But a disadvantage is encountered when one considers the cost of the immunoglobulin therapy, in regions where there are not adequate reimbursements for immunoglobulin and at the same instance, the patient is not prepared to undertake the significant burden of the cost of intravenous immunoglobulins. The early detection of primary immunodeficiency is ideal and optimum for the most effective treatment but in many of the emerging markets presents the huge opportunity for market players.

COVID-19 Impact:

The impact of COVID-19 pandemic has resulted in the disruption of production as well as distribution network due to logistic issues. Moreover, the impact on patient visits and shift of regular medical care to COVID care have resulted in negative impact on the global Intravenous Immunoglobulin (IVIg) market.

Global Intravenous Immunoglobulin Market

Source: Precise Market Intelligence, 2020

Segmentation:

The market has been segmented based on form, indication, end user and region.

  • By Form
    • Liquid
    • Lyophilized
       
  • By Indication
    • Primary Immunodeficiency
    • CIDP
    • Guillain-Barré Syndrome
    • Immune Thrombocytopenic Purpura (ITP)
    • Multifocal Motor Neuropathy
    • Others
       
  • By End user
    • Hospitals
    • Clinics
    • Homecare
       
  • By Region
    • North America (U.S., Canada)
    • Europe (U.K., France, Germany, Italy, Spain, and rest of Europe)
    • Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
    • South America (Brazil, Mexico, and Rest of South America)
    • Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa)

Based on form, the liquid segment dominates the market. This is attributed to availability of many products in the market and market players focusing on this form of product due to greater demand. Based on indication, Based on Indications Primary Immunodeficiency segment accounted to highest market share. While, the hospital segment dominated the end users, North America has the largest market share among regions.

Intravenous Immunoglobulin Market, By Region, 2019

Source: Precise Market Intelligence, 2020

Competition Landscape:

The global IVIg market is consolidated with few companies dominating the market. The dominance is due to their ability to manufacture the complex products and their geographical reach. The prominent companies in the market are; Shire (Takeda Pharmaceutical Company Limited), CSL, Kedrion S.p.A, Octapharma, Biotest AG, China Biologic Products Holdings, Inc., LFB SA, Shanghai RAAS Blood Products Co., Ltd. and others.

For better understanding of revenue contribution of each technology to the Intravenous Immunoglobulins Market, ask an expert analyst